Preclinical evidence of effective anti-myeloma effects of anti-CD38 CAR T-cell therapy66,67 has led to the initiation of various clinical trials, one of which investigates anti-CD38 CAR T cells as monotherapy in RRMM (NCT03464916), while others explore its combination with different CAR T cells, including anti-BCMA, anti-CD19, anti-CD138, anti-CD56, and anti-NY-ESO-13. The gene discussed is TNFRSF17; the disease is plasma cell myeloma.